ZDHHC9 and glioblastoma: To determine the clinical significance of the observed DHHC9-regulated GLUT1 PM localization, we next performed IHC analyses in GBM samples from 68 patients with anti-DHHC9 and anti-GLUT1 antibodies (Fig. 6a), revealing that DHHC9 expression levels were positively correlated with the percentage of GLUT1 PM localization (Fig. 6a).